View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 9, 2011

Positive trial results for Brainsway deep TMS system

Brainsway has reported additional interim results of a clinical trial being conducted at the Ichilov Medical Center in Israel to evaluate the efficacy of a deep transcranial magnetic stimulation (TMS) system in the treatment of Alzheimer's disease.

Brainsway has reported additional interim results of a clinical trial being conducted at the Ichilov Medical Center in Israel to evaluate the efficacy of a deep transcranial magnetic stimulation (TMS) system in the treatment of Alzheimer’s disease.

The interim study included 24 patients who were divided into three groups: a sham stimulation control group, a low-frequency treatment group and a high-frequency treatment group.

Each subject received treatment over eight weeks, and the efficacy of the treatment was evaluated both during the trial and over the course of the subsequent eight-week period.

Treatment using deep TMS was well-tolerated by all subjects, with no side-effects.

Efficacy was evaluated using the Alzheimer’s Disease Assessment Scale – Cognitive test and a quality-of-life scale.

The results suggest that high-frequency treatment leads to improvement on Alzheimer’s disease assessment scales, whereas low-frequency and sham treatment do not.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management